Stay updated on PATHWay Study: Adjuvant Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.

Latest updates to the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page
- Check6 days agoChange DetectedThe webpage has updated its date references, adding several dates in June 2025 while removing dates from May 2024.SummaryDifference0.8%
- Check13 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check20 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content or functionality of the page.SummaryDifference0.1%
- Check63 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study descriptions and eligibility criteria for a clinical trial on head and neck cancer, while adding a new revision number and the term 'Head and Neck Cancer'.SummaryDifference57%
- Check70 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to PATHWay Study: Adjuvant Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.